Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of BMS-986263 in compensated NASH cirrhosis
MOH_2021-02-03_009717Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ND-L02-s0201 in metabolic dysfunction-associated steatohepatitis (MASH), hepatic fibrosis and Cirrhosis (3 arms), sponsored by Bristol Myers Squibb. Started Nov 2020; status: completed.
02
Drugs
ND-L02-s0201
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosisCirrhosis
Beyond the preview
Go deeper on MOH_2021-02-03_009717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-03_009717.